MedTrace Logo

New Signaling Pathway Targeting Systemic Lupus Erythematosus

NCT03984227 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2019-06-28

No results posted yet for this study

Summary

Systemic lupus erythematosus is inflammatory autoimmune disease that affects over one million people in the United States. It has a higher prevalence and incidence rate among women compared with men, and among African Americans compared with Caucasians. Despite advances in treatment, standardized mortality rates in SLE remain three times higher than in the general population. The risk of mortality is significantly increased because of renal disease, cardiovascular disease, and infection.The etiology of SLE is multifactorial, with genetic predisposition, environmental factors and epigenetic alterations are involved. However, the molecular mechanisms underlying this systemic autoimmune response remain largely unknown. A key issue in the pathogenesis of lupus is how intracellular antigens become exposed and targeted by the immune system.

Conditions

Interventions

GENETIC

Taking peripheral blood samples

quantitative real-time polymerase chain reaction

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ghada M Ezzat, PhD · Department of Medical Biochemistry, Faculty of Medicine, Assiut University

  • Marwa A Gaber, PhD · Department of Medical Biochemistry, Faculty of Medicine, Assiut University

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-31
Primary Completion
2020-12-31
Completion
2021-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03984227 on ClinicalTrials.gov